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Abstract
Pretreatment variables that could predict the
response of chronic hepatitis C to interferon
alfa treatment have not been fully assessed.
Eighteen baseline variables were evaluated in a
series of 100 consecutive patients treated with
a 12 month course of interferon alfa. For the
purposes of this study, response was defined
as the return to normal of aminotransferase
activities before the third month of treatment.
Seventy per cent of the patients responded to
treatment. Six variables were associated with
an increased likelihood of response assessed
by univariate analysis. With stepwise multiple
regression analysis assessment, however, only
three variables remained independently pre-
dictive of response: low y glutamyltransferase
(yGT) activities (p<0.001), absence of obesity
(p=0.005), and absence of cirrhosis (p=0-01).
The response rate in patients with yGT activi-
ties <066 iikat/l (n=55) was 78% and 60% in
patients with values >066 ikat/l (n=45)
(p=.0048). Response was attained in 75% of
non-obese patients (n=80), compared with
only 50% of obese patients (n=20) (p=003).
Finally, 80% of patients without cirrhosis
(n=76) responded, while among those with
cirrhosis (n=24) the response rate was only
37% (p<0001). All 23 patients without cirrho-
sis, <40 years old, and with yGT activities
<0-66 tkat/l responded to treatment, while
only 28-5% of 14 patients with cirrhosis, >40
years old, and with yGT activities >0 66
pkat/l responded to interferon affa (p<0-001).
Those findings may be useful when evaluating
interferon alfa trials and it is suggested that this
treatment should be applied early in the course
of chronic hepatitis C.
(Gut 1993; 34: 1714-1717)
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Interferon alfa has been assessed in the treatment
of chronic hepatitis C in several trials. `6In most
studies normalisation of aminotransferase activi-
ties has been attained in about 50% of the
patients and relapses after stopping interferon
alfa are usually seen in half of the responders.6
Pretreatment parameters that might predict
response to interferon alfa have not been clearly
determined. In some trials predictive parameters
of response were not found.' 257 Other studies
have suggested, however, that the absence of
cirrhosis and a younger age predicted response to
interferon alfa.8-2 Different criteria when defin-
ing response to interferon alfa were used in these
reports, which might account for the discrep-
ancy. The knowledge of factors predictive of
response in chronic hepatitis C has a remarkable
clinical interest, as was the case in chronic
hepatitis B.'3
This study was aimed at assessing several
pretreatment clinical variables as predictors of
response to interferon alfa, in a series of 100
consecutive patients treated with a 12 month
course of lymphoblastoid interferon alfa.
Univariate analysis was followed by a stepwise
multiple regression analysis to evaluate the
independent predictive value of each variable.
Patients and methods
PATIENTS
One hundred patients with chronic hepatitis C
consecutively treated with the same schedule
of lymphoblastoid interferon alfa (Wellferon,
Wellcome Research Foundation, Beckhenham,
UK) were included in this study. Eighty four of
them had participated in a randomised control-
led trial of 12 month interferon alfa v no treat-
ment' and 16 patients were treated with the same
dose and schedule in an uncontrolled study. All
patients were treated between 1988 and 1991.
Interferon alfa was given in a stepdown schedule:
3 million units (MU) daily for two months, 3 MU
three times per week for three months, and 1 5
MU three times per week for seven months.
Before treatment all patients had a clinical
evaluation, including a medical history with
special attention to epidemiological data, analyti-
cal blood tests, and a percutaneous liver biopsy
performed within three months before treat-
ment. Other causes of chronic hepatitis were
carefully excluded. All patients, except three,
had anti-HCV antibodies by a second genera-
tion enzyme immunoassay (Ortho Diagnostic
Systems, Raritan, NJ). In all cases aminotrans-
ferase activities had been raised for at least six
months before starting treatment and the liver
biopsy showed chronic hepatitis with or without
cirrhosis. Patients with anti-HIV antibodies and
other serious medical illnesses were excluded.
All patients were instructed to stop alcohol
intake at least six months before starting treat-
ment. The trials were approved by the Local
Ethics Committee and written informed consent
was obtained from all patients.
As well as pretreatment variables, neutralising
anti-lymphoblastoid interferon alfa antibiodies
were assessed by a specific bioassay in a sample
collected during the last week of treatment in 15
of 30 patients who did not respond to treatment
to investigate their potential influence in non-
responsiveness. The bioassay is based on the
protective effect of lymphoblastoid interferon
alfa on monkey kidney V3 cells challenged with
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Semliki Forest virus and was performed as
described elsewhere.'4 Purified lymphoblastoid
interferon alfa of standard potency and con-
trol anti-serum samples (kindly supplied by
Wellcome Research Foundation, Beckenham,
UK) were used to confirm the specificity and
sensitivity of the assay.
DEFINITION OF RESPONSE
Response was defined as a complete normalisa-
tion of aminotransferase activities before the
third month of treatment and persisting at least
until the fifth month ofthe interferon alfa course.
The initiation of the response beyond the third
month of treatment was not seen in any case. For
the present analysis those patients who had
responded initially and relapsed when the inter-
feron dose was tapered to 1-5 MU three times per
week at five months were considered responders.
All other patients, including 16 whose alanine
aminotransferase (ALT) activities decreased by
more than 50% but did not return to normal,
were considered non-responders. Our definition
ofresponse was intended to assess the capacity of
interferon alfa for inducing a biochemical remis-
sion of the disease.
PRETREATMENT VARIABLES
Eighteen pretreatment variables were assessed in
each patient: age, sex, history of acute hepatitis
and transfusions, presence of obesity defined by
a body weight >20% the ideal weight (deter-
mined with an age/sex based standard table), and
the estimated time of evolution considered as the
interval between an obvious percutaneous risk
factor (for example, transfusion) or the first
detected ALT rise and the start of treatment,
were all recorded from the clinical history ofeach
patient. Liver biopsy specimens were classified
into two groups by an experienced liver patholo-
gist: chronic hepatitis (either persistent (five
cases) or active (71 cases)) and active cirrhosis.
Presence of fatty degeneration of hepatocytes
was also assessed. Before starting treatment
ALT (normal range: 0 10-0 48 [tkat/l), alkaline
phosphatase (normal range: 1 21-3-45 [tkat/l), y
glutamytransferase (yGT) (normal range: 0-08-
0-63 pkat/l), albumin, and y globulin values, as
well as neutrophil and platelet counts, were
determined in each case. Procollagen type III
aminoterminal peptide, a marker of fibrosis and
inflammatory activity,'5 was assessed using a
commercial radioimmunoassay kit ( RIA-gnost
PIIIP, Behringwerke AG, Marburg, Germany).
Anti-nuclear and anti-smooth muscle antibodies
were assessed by indirect immunofluorescence
and titres higher than 1/80 were considered
positive.
STATISTICS
Univariate analysis was applied to each variable
to assess its association with response to inter-
feron alfa treatment. X2 and Fisher's exact tests
were used for dichotomous variables, and
Student's t test for continuous variables. Time of
evolution and yGT were logarithmically trans-
formed before analysis. Cathegorical explana-
tory variables were transformed to 0/1 dummy
variables.'6 Stepwise multiple linear regression
analysis (Stat View SE+graphics, 1988 Abacus
Concepts Inc, Berkeley, CA) was subsequently
applied to all variables to assess their indepen-
dent predictive value. Statistical significance was
assumed where p-0 05 and all p values are two
tailed.
Results
UNIVARIATE ANALYSIS
Seventy per cent of the patients responded to
treatment (as defined in the methods section),
while the remaining 30% did not. Table I shows
the results of the univariate analysis. Six vari-
ables were found to be significantly associated
with treatment response. Response to interferon
alfa was significantly more frequent in the young
(p<0-001), in patients without cirrhosis
(p<0001), and in patients with low yGT values
(p=0 003). The remaining three predictive vari-
ables were less strongly associated with response
to interferon alfa (Table I). Absence of obesity,
male sex, and a high platelet count predicted
response to interferon alfa. Only 37% of the
patients with cirrhosis (n=24) responded to
interferon alfa, while in 80% of the patients with
chronic hepatitis (n=76) aminotransferase
activities returned to normal (p<0-001). The
response rate among patients <45 years (n=39)
was 92%, while it decreased to 56% in patients
>45 years (n=61) (p<0-001). Patients with yGT
values 60-66 [ikat/l had a response rate of 78%,
while response was obtained in only 60% of the
patients with higher yGT values (p=0 048). All
patients (n=23) without cirrhosis, <40 years,
and with yGT values <0'66 [tkat/l responded to
interferon alfa while only 64% of non-cirrhotic
patients, >53 years or with yGT values >1-00
iikat/l (n=28), or both responded to this treat-
ment. In contrast, the response rate was only
28-5% among patients with cirrhosis, >40 years
and with yGT values >0 66 ikat/l (n= 14).
When univariate analysis was applied to the
patients divided by liver histological tests into
TABLE I Univariate analysis ofpretreatment variables
Non-
Responders responders
Variable (n= 70) (n=30) p Value
Age (y)* 42-7 53-5 <0 001
Sex (M/F) 46/24 13/17 0 04
Obesity (%) 14 33 0 03
Acute hepatitis (%) 30 27 NS
Transfusions (%) 53 40 NS
Time of evolution (months)* 46-6 58-7 NS
ALT (Rkat/l)*at 2-66 2-36 NS
Alkaline phosphatase(Rkat/l)*bt 2-61 2-36 NS
yGT ([tkat/l)*ct 0-61 0-91 0 003
Neutrophils (109/l)* 3-08 2 70 NS
Platelets (109/1)* 179 152 0-02Album,in (g/l)* 42-9 41-1 NS
y Globulins (g/l),* 13-7 15-3 NSPIIIP(ng/ml)* t 18-7 219 NS
ANA positive (%) 9 3 NS
SMA positive (%) 17 13 NS
Chronic hepatitis/cirrhosis 61/9 15/15 <0-001
Fatty degeneration (%) 34 50 NS
*Results presented as means. tNormal ranges: (a) 0 10-0 48
stkat/l, (b) 1-21-3-45 skat/l, (c) 0-08-063 [skat/l, (d) 6-12 ng/mL.
ALT= alanine aminotransferase; yGT= glutamyltransferase;
PIIIP=procollagen aminoterminal peptide; ANA=anti-nuclear
antibodies; SMA=anti-smooth muscle antibodies.
1715
 group.bmj.com on August 2, 2012 - Published by gut.bmj.comDownloaded from 
Camps, Cris6stomo, Garcfa-Granero, Riezu-Boj, Civeira, Prieto
TABLE II Univariate analysis ofpretreatment variables in
patients with chronic hepatitis
Non-
Responders responders
Variable (n=61) (n=15) p Value
Age (y)* 40-9 51-6 0-008
Sex (M/F) 40/21 6/9 NS
Obesity (%) 16 47 0-01
Acute hepatitis (%) 33 20 NS
Transfusions (%) 56 40 NS
Time of evolution (months)* 42-9 59 0 NS
ALT (,tkat/l)* 2-66 2-38 NS
Alkaline phosphatase (Rkat/l)* 2-55 2-16 NS
yGT (,ukat/l)* 0-56 0 90 0-03
Neutrophils (109/l)* 3-12 2-92 NS
Platelets (109/l)* 188 158 0-05
Albumin (g/l)* 43-3 42-7 NS
y Globulins (g/l)* 13-5 13-4 NS
PIIIP (ng/ml)* 17-8 16-6 NS
ANA positive (%) 7 7 NS
SMA positive (%) 16 7 NS
Fatty degeneration (%) 34 47 NS
*Results presented as means.
Abbreviations the same as in Table I.
two groups (chronic hepatitis/cirrhosis), among
patients with cirrhosis (n=24), none of the
variables predicted response, while among
patients without cirrhosis (n=76), young age,
absence of obesity, low yGT values, and a high
platelet count were all associated with response
(Table II).
Neutralising anti-lymphoblastoid interferon
alfa antibodies were detected in only one
of 15 patients tested who did not respond
(7%).
STEPWISE MULTIPLE LINEAR REGRESSION
ANALYSIS
Stepwise multiple regression analysis showed
that yGT values (p<0-001), obesity (p=0-005)
and histological tests (p=0 01) were the only
independently predictive variables. Low yGT
values, the absence ofobesity, and the absence of
cirrhosis were all independently associated with
a positive response to interferon alfa. The
remaining pretreatment variables found predic-
tive on univariate analysis added no further
improvement in discrimination. Total body
weight did not influence the response to treat-
ment because the mean weight of responders and
non-responders was similar (kg; responders:
mean (SEM) 66-9 (12-7), non-responders: 67-5
(9-2)). Therefore, it was obesity itself, rather
than total weight, which seemed to influence
response.
Stepwise multiple regression analysis was also
applied to the group of patients with cirrhosis
(n=24) without finding significantly predictive
variables, although obesity, fatty degeneration of
hepatocytes, and high y globulin values tended
to correlate with non- response. None of the
responders were obese while 20% of the non-
responders were obese; fatty degeneration was
present in 33% of the responders and in 53% of
the non-responders; mean ((SD), g/l) y globulin
values in responders were: 15-1 (4-9), compared
with 17-3 (4-8) in non-responders. Among
patients without cirrhosis (n=76) a low yGT
value (p<0 001), the absence of obesity (p=
0-008), and a high platelet count (p-002) were
independently associated with response to inter-
feron alfa.
Discussion
It has not been clearly established if pretreat-
ment variables that might predict the response of
chronic hepatitis C to interferon alfa do exist.'2
Some studies did not find predictive vari-
ables,' 2I 7 while others gave quite disparate
results.8'- 17 These discrepancies may be attrib-
uted to the small number of patients included in
some studies, to different criteria for defining
response, and to shortcomings in the statistical
analyses. Some of these analyses were only
univariate. Moreover, some studies have com-
pared patients treated with different doses of
interferon alfa and it has been established that
different schedules ofinterferon alfa may achieve
different response rates.3 In this study, we
clearly show, in a large series of patients consecu-
tively treated with the same schedule of inter-
feron alfa, that some pretreatment variables may
independently predict response to this treat-
ment. The criteria we have used for the defini-
tion of response were intended to assess the
ability of interferon alfa to achieve a clear cut
biochemical response, which is usually associ-
ated with a transient or sustained clearance of
serum HCV RNA.'5 Spontaneous normalisa-
tions of ALT activities have only been seen in
about 1% of controls in randomised trials.6
Relapses during treatment, which were seen in
15 patients when receiving the lower doses of
interferon alfa (1-5 MU, three times per week),
and relapses occurring after interferon alfa was
stopped were not taken into account.
The finding that most young patients (<45
years) without cirrhosis will respond to treat-
ment (95%), while only one third (36%) of the
patients >45 years and with established cirrhosis
will benefit from treatment is clinically relevant.
This finding emphasises the need for early
treatment in chronic hepatitis C. In addition,
this might explain the discrepancies in the
response rates among different clinical trials,
which could be because of differences in the
characteristics of the populations studied. The
reason why yGT values influence response to
interferon alfa is not known. It could be specu-
lated that a rise in yGT values might merely
reflect an as yet undefined change in liver
function, which might somehow impair response
to treatment. In fact some preliminary studies
have suggested that ursodeoxycolic acid, which
decreases yGT and alkaline phosphatase values
in some cholestatic liver diseases, might enhance
interferon alfa activity in chronic hepatitis C. '9 A
preliminary report has also found yGT values to
be the best predictor of response to interferon
alfa.20 Unfortunately, most studies have not
evaluated the influence of this variable.
The reason why patients with cirrhosis do not
respond as well to interferon alfa as patients
without cirrhosis is unknown. It can be specu-
lated, however, that host and virological factors
could both influence response to interferon alfa.
Cirrhosis has been associated with immune
changes2' 22 and it is usually seen after many years
of infection. Immune selected HCV mutants
resistant to interferon alfa treatment might
appear in cases with a long evolution of the
disease.2324 It has been shown that HCV, like
most RNA viruses, circulates as a population
1716
 group.bmj.com on August 2, 2012 - Published by gut.bmj.comDownloaded from 
Prediction ofthe response ofchronic hepatitis C to interferon alfa: a statistical analysis ofpretreatment variables 1717
of closely related but none the less distinct
genomes, a finding that implies a high capacity to
generate escape mutants.25 In addition, cirrhosis
may change the pharmacokinetics of some drugs
and that could be the case with interferon.
The mechanism by which obesity may
adversely influence response also remains
unknown. One study found significant differ-
ences in the mean weight between responders
and non-responders.26 We found no differ-
ences, however, when assessing the total body
weight. Interferon alfa bioavailability could be
diminished in obese patients because of a
decrease in the absorption of the drug when the
subcutaneous route is used, as in this study.
Other studies have shown that the skinfold
thickness inversely correlates with the sub-
cutaneous absorption of some drugs.27 Pharma-
cokinetic studies should solve this issue.
Meanwhile, we would favour the intramuscular
route in obese patients.
Neutralising anti-lymphoblastoid interferon
alfa antibodies do not seem to play a significant
part in non-response to treatment, as they were
detected in only one of 15 non-responders tested.
This low frequency of detection is in accordance
with a recent study, which detected neutralising
antibodies in one of 78 treated patients, and
contrasts with the higher frequencies seen with
recombinant interferon alfa preparations.28
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